Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
The Prostate · 2025
DOI: 10.1002/pros.24821 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Prostate, 2025. Verfasst von Toshifumi Takahashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Image-Guided Biopsy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Objectives
To compare the detection rates for clinically significant prostate cancer (csPCa; grade group 2 or higher disease) using MRI‐targeted biopsy (MRI‐TB) versus systematic biopsy (SB) or their combination, and identify risk factors for detecting csPCa in MRI‐TB with systematic transrectal (TR)/transperineal (TP) biopsies (sTR/TP‐bx) and MRI‐TB with sTP‐bx.
Methods
We retrospectively analyzed 216 patients who underwent MRI‐TB with SB at our hospital between September 2020 and December 2023 and compared clinical characteristics for patients with and without prostate cancer. Results csPCa was detected in 132 (61.1%) patients by MRI‐TB with sTR/TP‐bx, in 121 (56.0%) patients using MRI‐TB with sTP‐bx, and in 101 (46.8%) patients using MRI‐TB. Older age, higher PSA density (PSAD), smaller prostate volume, region of interest in the peripheral zone, higher Prostate Imaging‐Reporting and Data System (PI‐RADS), and administration of dutasteride were more common in csPCa cases. A scoring system was constructed based on odds ratios for PSAD, PI‐RADS ≥ 4, and administration of dutasteride; accordingly, the detection rate of csPCa was 20.3% (14/69) in the low‐risk group (RG) and 95.5% (42/44) in high RG for MRI‐TB with sTR/TP‐bx, and 16.7% (12/72) in the low RG and 97.8% (45/46) in high RG for MRI‐TB with sTP‐Bx.
Conclusions
The addition of SB increased the detection rate of csPCa compared with MRI‐TB alone. PSAD, PI‐RADS ≥ 4, and administration of dutasteride significantly affect the detection of csPCa using MRI‐TB with SB and can be used for deciding whether to perform a biopsy or include sTR‐bx with MRI‐TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
- Department of Diagnostic Radiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
ORCID-Profile: Toshifumi Takahashi, Kazuro Kikkawa
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Takahashi, T., Nakashima, M., Maruno, K., Hazama, T., Yamada, Y., Kikkawa, K., Umeoka, S., Tamaki, M., & Ito, N. (2025). Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System. The Prostate. https://doi.org/10.1002/pros.24821
Vancouver
Takahashi T, Nakashima M, Maruno K, Hazama T, Yamada Y, Kikkawa K, et al. Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System. The Prostate. 2025. doi:10.1002/pros.24821
BibTeX
@article{Takahashi2025,
author = {Takahashi, Toshifumi and Nakashima, Masakazu and Maruno, Kouhei and Hazama, Tatsuya and Yamada, Yuya and Kikkawa, Kazuro and Umeoka, Shigeaki and Tamaki, Masahiro and Ito, Noriyuki},
title = {Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24821}
}
EUVIMED